Asian Phytoceuticals PCLBKK:APCO-R 62 Debt-to-EBITDA is 0.09 as of Mar. 2026, which is 64% below its 10-year median of 0.25. GuruFocus rates BKK:APCO-R with a GF Score™ of 62/100 and a GF Value™ of ฿7.61. The stock has 4 warning signs investors should review. Among 1,536 Consumer Packaged Goods companies, Asian Phytoceuticals PCL ranks better than 92.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Asian Phytoceuticals PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:APCO-R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1 Med: 0.25 Max: 0.42
Current: 0.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Asian Phytoceuticals PCL was 0.42. The lowest was 0.10. And the median was 0.25.
BKK:APCO-R's Debt-to-EBITDA is ranked better than 92.06% of 1536
companies
in the Consumer Packaged Goods industry
Industry Median: 2.06
vs BKK:APCO-R: 0.10
Asian Phytoceuticals PCL (BKK:APCO-R) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Asian Phytoceuticals PCL Debt-to-EBITDA Related Terms
Asian Phytoceuticals PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:APCO-R vs PG, CL, KVUE: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, Asian Phytoceuticals PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asian Phytoceuticals PCL Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Asian Phytoceuticals PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Asian Phytoceuticals PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Asian Phytoceuticals PCL (BKK:APCO-R) has a Debt-to-EBITDA of 0.09 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asian Phytoceuticals PCL. This is 64% below median its historical median of 0.25. Over the past decade, Asian Phytoceuticals PCL's Debt-to-EBITDA has ranged from 0.10 to 0.42. According to the industry distribution chart, Asian Phytoceuticals PCL ranks #122 out of 1536 companies in the Consumer Packaged Goods industry, placing it in the top 7.9%.
Is Asian Phytoceuticals PCL's Debt-to-EBITDA too high?
Asian Phytoceuticals PCL's current Debt-to-EBITDA of 0.09 is 64% below median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.42. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.06. Asian Phytoceuticals PCL's value of 0.09 is 95.6% below this industry median. Based on the distribution chart, Asian Phytoceuticals PCL ranks #122 out of 1536 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Asian Phytoceuticals PCL has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Asian Phytoceuticals PCL's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Asian Phytoceuticals PCL ranks #122 out of 1536 companies for Debt-to-EBITDA. This places Asian Phytoceuticals PCL in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.06. Asian Phytoceuticals PCL's value of 0.09 is 95.6% below this benchmark. Historically, Asian Phytoceuticals PCL's own Debt-to-EBITDA has ranged from 0.10 to 0.42 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 2.06, Asian Phytoceuticals PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.06, based on 1,536 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asian Phytoceuticals PCL's current Debt-to-EBITDA of 0.09 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asian Phytoceuticals PCL. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asian Phytoceuticals PCL's current Debt-to-EBITDA is 0.09, which is 64% below median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asian Phytoceuticals PCL stock overvalued right now?
Asian Phytoceuticals PCL (BKK:APCO-R) has a current Debt-to-EBITDA of 0.09. The stock's GF Value™ is ฿7.61, compared to a current price of ฿6.27 — trading 17.6% below its estimated fair value. The current Debt-to-EBITDA is 0.09, which is 64% below median its 10-year median of 0.25 and 95.6% below the Consumer Packaged Goods industry median of 2.06. Asian Phytoceuticals PCL's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Asian Phytoceuticals PCL (BKK:APCO-R), the current Debt-to-EBITDA is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asian Phytoceuticals PCL (BKK:APCO-R) Overvalued in 2026?
Based on GuruFocus' analysis, Asian Phytoceuticals PCL stock appears to be undervalued.
The current stock price of ฿6.27 is trading 17.6% below its estimated GF Value™ of ฿7.61.
Key valuation signals for BKK:APCO-R:
Debt-to-EBITDA: 0.09 (64% below median its 10-year median of 0.25)
GF Value™: ฿7.61 vs. price of ฿6.27 (17.6% below fair value)
Industry Position: 95.6% below the Consumer Packaged Goods median (#122 of 1536)
No single metric tells the full story. See the BKK:APCO-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asian Phytoceuticals PCL engages in the manufacturing and marketing of herbal healthcare products. The company engages in the production and distribution of dietary supplements, cosmetics, and personal care products made from natural herbs. Its beauty products include skin nourishing and skin care products, hair loss treatment and hair growth products, slimming products, dietary supplements, and other nutritional products. Geographically, the company offers its services only in Thailand.
62GF Score
Get the complete analysis for BKK:APCO-R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:APCO-R has been successfully added to your 
